Statistics for Fate Therapeutics (id:6524 FATE)

Valuation metrics

Market cap

260.82M

Enterprise value

37.82M

Trailing P/E (ttm)

-1.40

Forward P/E

-1.36

PEG ratio

-1.36

Price/Sales (ttm)

19.40

Price/Book (mrq)

0.72

Enterprise Value/Revenue

2.81

Enterprise Value/EBITDA

-0.23

Overview

Shares outstanding

113.89M

Float

98.79M

Shares short

15.90M

% Held by insiders

0.02%

% Held by institutions

1.02%

Average volume (10 days)

4.48M

Average volume (90 days)

Price summary

52-Week low

1.96

52-Week high

8.83

52-Week change

-3.06%

Beta

1.88

50-Day moving average

2.99

200-Day moving average

4.40

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-1,703.87%

Operational effectiveness

Return on assets

-22.11%

Return on equity

-46.59%

Income statement

Revenue (ttm)

0.12

Revenue per share (ttm)

0.12

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-164,668,992.00

Net income to common (ttm)

-178,231,008.00

Diluted EPS (ttm)

-1.64

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

296.92M

Total cash per share (mrq)

2.61

Total debt (mrq)

98.98M

Total Debt/Equity (mrq)

27.32

Current ratio (mrq)

829.20%

Book value per share (mrq)

3.18

Cash flow

Cash flow statement

-131,712,000.00

Levered free cash flow (LFCF)

-58,500,376.00